August 21, 2026

• CDER Statement: FDA Publishes New Product-Specific Guidances to Facilitate Generic Drug Development
• Final Guidance: Evaluation of Therapeutic Equivalence

August 18, 2026

• Public Notifications:
  • Esbelta Chupapanza Flat Belly may be harmful due to hidden ingredient
  • Esbelta Intense Loss may be harmful due to hidden ingredients

This report displays final approvals and tentative approvals of original and supplemental applications for the two days beginning on the earliest date listed below. Some approvals may be added to the Drugs@FDA database after this time span. For comprehensive approval reports, please use the monthly "All Approvals" report on Drugs@FDA.